Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$2.16B |
| 2 |
Hershey
HSY
|
+$663M |
| 3 |
Lockheed Martin
LMT
|
+$622M |
| 4 |
Altria Group
MO
|
+$525M |
| 5 |
Pfizer
PFE
|
+$499M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$2.76B |
| 2 |
Merck
MRK
|
+$2.35B |
| 3 |
Automatic Data Processing
ADP
|
+$1.57B |
| 4 |
Blackstone
BX
|
+$1.38B |
| 5 |
Illinois Tool Works
ITW
|
+$1.13B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.85% |
| 2 | Financials | 12.71% |
| 3 | Healthcare | 11.72% |
| 4 | Consumer Discretionary | 10.09% |
| 5 | Industrials | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2951
Orange County Bancorp
OBT
$517M
| $614K | ﹤0.01% |
26,678
| – | – |
|
2952
Ezcorp Inc
EZPW
$1.85B
| $613K | ﹤0.01% |
54,112
+9,437
| +21% | +$93.1K |
|
2953
CorMedix
CRMD
$588M
| $612K | ﹤0.01% |
144,417
-6,877
| -5% | -$23.8K |
|
2954
Accuray
ARAY
$31.6M
| $612K | ﹤0.01% |
247,724
-11,193
| -4% | -$30K |
|
2955
Immersion
IMMR
$242M
| $607K | ﹤0.01% |
81,209
-3,451
| -4% | -$24.6K |
|
2956
Prelude Therapeutics
PRLD
$351M
| $604K | ﹤0.01% |
127,370
+2,670
| +2% | +$10.4K |
|
2957
Fidelity D&D Bancorp
FDBC
$312M
| $603K | ﹤0.01% |
12,446
| – | – |
|
2958
Red Violet
RDVT
$967M
| $602K | ﹤0.01% |
30,805
| – | – |
|
2959
Nokia
NOK
$52.2B
| $602K | ﹤0.01% |
169,990
+136,673
| +410% | +$486K |
|
2960
Cricut
CRCT
$1B
| $600K | ﹤0.01% |
126,061
-5,648
| -4% | -$30.1K |
|
2961
BayCom
BCML
$338M
| $600K | ﹤0.01% |
29,091
-2,013
| -6% | -$41.5K |
|
2962
Actinium Pharmaceuticals
ATNM
$26M
| $597K | ﹤0.01% |
76,208
| – | – |
|
|
IAUX
2963
i-80 Gold Corp
IAUX
$1.13B
| $595K | ﹤0.01% |
444,218
| – | – |
|
2964
John Marshall Bancorp
JMSB
$335M
| $590K | ﹤0.01% |
32,930
| – | – |
|
|
ITI
2965
DELISTED
Iteris, Inc.
ITI
| $589K | ﹤0.01% |
119,272
| – | – |
|
2966
Bit Digital
BTBT
$484M
| $586K | ﹤0.01% |
204,171
| – | – |
|
|
TUYA
2967
Tuya Inc
TUYA
$1.05B
| $585K | ﹤0.01% |
334,386
| – | – |
|
2968
Intrepid Potash
IPI
$444M
| $583K | ﹤0.01% |
27,970
-1,387
| -5% | -$27.7K |
|
2969
Seres Therapeutics
MCRB
$49M
| $578K | ﹤0.01% |
37,366
+3,547
| +10% | +$76.5K |
|
2970
Donegal Group Class A
DGICA
$734M
| $576K | ﹤0.01% |
40,709
-975
| -2% | -$13.8K |
|
2971
Vanguard Consumer Discretionary ETF
VCR
$6.26B
| $574K | ﹤0.01% |
1,805
-51
| -3% | -$15.6K |
|
|
CVLY
2972
DELISTED
Codorus Valley Bancorp Inc
CVLY
| $569K | ﹤0.01% |
25,016
-1,304
| -5% | -$30.5K |
|
2973
Spyre Therapeutics
SYRE
$8.24B
| $569K | ﹤0.01% |
+15,000
| New | +$435K |
|
2974
CVRx
CVRX
$146M
| $569K | ﹤0.01% |
31,233
| – | – |
|
|
AFCG
2975
AFC Gamma
AFCG
$60.9M
| $566K | ﹤0.01% |
66,820
| – | – |
|
Similar funds
Charles Schwab's Q1 2024 Portfolio in Review
As of Q1 2024, Charles Schwab held 3,573 positions worth $433B, up 10% from $394B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Trading was light in Q1 2024: portfolio turnover was 3.8%. Charles Schwab opened 35 new positions and exited 102, leaving the 3,573-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q1 2024 buy was Schwab Fundamental US Large Company Index ETF: 3,608,604 shares worth $81.1M.
- Charles Schwab added most to Bristol-Myers Squibb in Q1 2024, an estimated $2.16B increase.
- Charles Schwab's biggest Q1 2024 reduction was Broadcom, cutting an estimated $2.76B.
- Charles Schwab fully exited Splunk Inc in Q1 2024, selling an estimated $104M.
- Charles Schwab's ten largest holdings make up 20% of its $433B portfolio in Q1 2024.
- Charles Schwab opened 35 new positions and closed 102 in Q1 2024.
- Charles Schwab's portfolio value rose 10% quarter-over-quarter to $433B.
Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.